UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 513

Sortiert nach

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Annals of oncology, 2017-06, Vol.28 (6), p.1207-1216

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Annals of oncology, 2022-04, Vol.33 (4), p.416-425

2022

Link zum Volltext

Verfügbarkeit prüfen

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Annals of oncology, 2018-08, Vol.29 (8), p.1727-1740

2018

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic therapies in gastric cancer: trusting the pathway

Annals of oncology, 2016-12, Vol.27 (12), p.2141-2143

2016

Link zum Volltext

Verfügbarkeit prüfen

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Annals of oncology, 2019-10, Vol.30 (10), p.1670-1670

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Annals of oncology, 2018-07, Vol.29 (7), p.1605-1605

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s

Annals of oncology, 2018-11, Vol.29, p.ix49-ix50

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

Annals of oncology, 2018-06, Vol.29, p.v100-v100

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer

Annals of oncology, 2018-10, Vol.29, p.viii268-viii269

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors

Annals of oncology, 2018-10, Vol.29, p.viii123-viii123

2018

Link zum Volltext

Verfügbarkeit prüfen

Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Annals of oncology, 2018-10, Vol.29, p.viii653-viii653

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress

Annals of oncology, 2018-06, Vol.29, p.v14-v15

2018

Link zum Volltext

Verfügbarkeit prüfen

Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)

Annals of oncology, 2018-10, Vol.29, p.viii28-viii28

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

Annals of oncology, 2018-10, Vol.29, p.viii45-viii45

2018

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

European journal of cancer (1990), 2016-12, Vol.69, p.S14-S15

2016

Link zum Volltext

Verfügbarkeit prüfen

Isquemia mesentérica: manejo endovascular

Revista médica herediana, 2021-07, Vol.32 (2), p.123-130

2021

Link zum Volltext

Verfügbarkeit prüfen

Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials

European journal of cancer (1990), 2016-12, Vol.69, p.S42-S42

2016

Link zum Volltext

Verfügbarkeit prüfen

3032A Activity and safety profile of lucitanib in patients with advanced thymic epithelial tumours

European journal of cancer (1990), 2015-09, Vol.51, p.S607-S607

2015

Link zum Volltext

Verfügbarkeit prüfen

Influence of Treatment Received in Long-Surviving Patients of Head-and-Neck Cancer

International journal of radiation oncology, biology, physics, 2014-02, Vol.88 (2), p.531-532

2014

Link zum Volltext

Verfügbarkeit prüfen

Focal nodular hyperplasia on accessory lobe of the liver: Preoperative diagnosis and management

Journal of pediatric surgery, 2013, Vol.48 (1), p.251-254

2013

Link zum Volltext

Verfügbarkeit prüfen

386 PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vall d'Hebron experience

European journal of cancer (1990), 2014-11, Vol.50, p.124-124

2014

Link zum Volltext

Verfügbarkeit prüfen

2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients

European journal of cancer (1990), 2015-09, Vol.51, p.S470-S470

2015

Link zum Volltext

Verfügbarkeit prüfen

PO-081: Late Toxicity After Radical Treatment for Locally Advanced Head-and-Neck Carcinomas

Radiotherapy and oncology, 2013-02, Vol.106, p.S34-S35

2013

Link zum Volltext

Verfügbarkeit prüfen

Functionality of Bread and Beverage Added with Brosimum alicastrum Sw. Seed Flour on the Nutritional and Health Status of the Elderly

Foods, 2021-07, Vol.10 (8), p.1764

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 513

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(434)
Mit Volltextzugriff
(440)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(239)
Life Sciences & Biomedicine
(160)
Humans
(147)
Female
(88)
Male
(87)
Biological And Medical Sciences
(65)
Physical Sciences
(63)
Child
(53)
Technology
(51)
Child, Preschool
(43)
Infant
(43)
Medical Sciences
(43)
Adolescent
(39)
Materials Science
(39)
Adult
(37)
Exact Sciences And Technology
(33)
Physics
(33)
Chemistry
(27)
Food Science & Technology
(27)
Fundamental And Applied Biological Sciences. Psychology
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Antiangiogenic therapies in gastric cancer: trusting the pathway

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer

Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors

Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress

Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)

Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

Isquemia mesentérica: manejo endovascular

Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials

3032A Activity and safety profile of lucitanib in patients with advanced thymic epithelial tumours

Influence of Treatment Received in Long-Surviving Patients of Head-and-Neck Cancer

Focal nodular hyperplasia on accessory lobe of the liver: Preoperative diagnosis and management

386 PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vall d'Hebron experience

2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients

PO-081: Late Toxicity After Radical Treatment for Locally Advanced Head-and-Neck Carcinomas

Functionality of Bread and Beverage Added with Brosimum alicastrum Sw. Seed Flour on the Nutritional and Health Status of the Elderly

Suchergebnisse filtern